Brainstorm's cell therapy safe, well tolerated in ALS study

Drug developer Brainstorm Cell Therapeutics Inc said its experimental cell therapy was found safe and well tolerated in patients with amyotrophic lateral sclerosis (ALS), a progressive neurological disorder, in a mid-stage study.

The New Jersey-based company's shares jumped 16 percent to $3.47 in premarket trading on Monday.

More on this...

ALS is an invariably fatal neurological disease that attacks the nerve cells responsible for controlling voluntary muscles.

The drug, NurOwn, also showed a clinically meaningful benefit compared with a placebo, Brainstorm said.